Cidara Therapeutics (CDTX) Other Gross PP&E Adjustments: 2017-2025
Historic Other Gross PP&E Adjustments for Cidara Therapeutics (CDTX) over the last 7 years, with Sep 2025 value amounting to -$1.8 million.
- Cidara Therapeutics' Other Gross PP&E Adjustments rose 40.86% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year increase of 41.90%. This contributed to the annual value of -$285,000 for FY2024, which is 80.55% up from last year.
- Cidara Therapeutics' Other Gross PP&E Adjustments amounted to -$1.8 million in Q3 2025, which was up 15.33% from -$2.1 million recorded in Q2 2025.
- In the past 5 years, Cidara Therapeutics' Other Gross PP&E Adjustments registered a high of $896,000 during Q4 2022, and its lowest value of -$4.3 million during Q2 2023.
- In the last 3 years, Cidara Therapeutics' Other Gross PP&E Adjustments had a median value of -$2.4 million in 2025 and averaged -$2.5 million.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first plummeted by 347.59% in 2021, then skyrocketed by 169.73% in 2022.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Other Gross PP&E Adjustments stood at -$1.3 million in 2021, then spiked by 169.73% to $896,000 in 2022, then slumped by 263.50% to -$1.5 million in 2023, then spiked by 80.55% to -$285,000 in 2024, then soared by 40.86% to -$1.8 million in 2025.
- Its last three reported values are -$1.8 million in Q3 2025, -$2.1 million for Q2 2025, and -$2.4 million during Q1 2025.